Bcl-2 antisense therapy in B-cell malignant proliferative disorders

Current Treatment Options in Oncology

Volumn 5, Issue 4, 2004, Pages 261-267

  Chanan Khan, Asher ^a   Czuczman, Myron S ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; OBLIMERSEN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CARCINOGENESIS; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIZATION; DRUG TARGETING; FATIGUE; FEVER; GENE OVEREXPRESSION; HUMAN; HYPOTENSION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MOUSE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; VALIDATION PROCESS;

EID: 4344661301     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0017-3     Document Type: Review

References (28)

1. Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997, 34(Suppl 5):9-19.
2. Reed JC: Bcl-2 family proteins. Oncogene 1998, 17:3225-3236.
3. Tsujimoto Y, Gorham J, Cossman J, et al.: The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985, 229:1390-1393.
4. Wang HG, Reed JC: Mechanisms of Bcl-2 protein function. Histol Histopathol 1998, 13:521-530.
5. Lai R, Arber DA, Chang KL, et al.: Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol 1998, 11:864-869.
6. Gascoyne RD, Adomat SA, Krajewski S, et al.: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:244-251.
7. Milner AE, Grand RJ, Vaughan AT, et al.: Differential effects of Bcl-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation. Oncogene 1997, 15:1815-1822.
8. Logsdon MD, Meyn RE Jr, Besa PC, et al.: Apoptosis and the Bcl-2 gene family: patterns of expression and prognostic value in stage I and II follicular center lymphoma. Int J Radiat Oncol Biol Phys 1999, 44:19-29.
9. Martinka M, Comeau T, Foyle A, et al.: Prognostic significance of t(14;18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma. Clin Invest Med 1997, 20:364-370.
10. Ramanarayanan J, Chanan-Khan A, Czuczman MS: Genasense Targeting Bcl-2 Protein Expression Enhances the Biological Anti-tumor Activity of Rituximab Against Non-Hodgkins (NHL) Cell Lines and Lymphoma Xerografts. San Diego: American Society of Hematology, 2003.
11. van de Donk NW, Kamphuis MM, van Dijk M, et al.: Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003, 17:211-219.
12. Lebedeva I, Stein CA: Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol 2001, 41:403-419.
13. Liu Q, Gazitt Y. Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood 2003, 101:4105-4114.
14. Zhang Y, Shen WL: Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide. Cell Biol Int 2003, 27:953-958.
15. Zhang Y, Lei XY. Effect of bcl-2 antisense oligodeoxynucleotides on drug sensitivity of leukemic cells. Hematol J 2003, 4:187-197.
16. Auer R, Corbo M: Bcl-2 antisense (Genasense) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells [abstract). Blood 2001, 98(Suppl 1):808a.
17. Pepper C, Hooper K, Thomas A, et al.: Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Leuk Lymphoma 2001, 42:491-498.
18. van de Donk NW: G3139, a Bcl-2 Antisense Oligodeoxynucleotide, Induces Clinical Responses in VAD-refractory Myeloma. San Diego: American Society of Hematology; 2003.
19. Czuczman M: Pathways Involved in the Emergence of Resistance to Rituximab in Non-Hodgkin's Lymphoma (NHL) Cell Lines. San Diego: American Society of Hematology; 2003.
20. O'Connor O: Oblimersen (Bcl-2 Antisense) Enhances the Antitumor Activity of Bortezomib (Bor) in Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL). San Diego: American Society of Hematology; 2003.
21. Frankel SR: Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenström's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol 2003, 30:300-304.
22. Jansen B, Wacheck V, Heere-Ress E: Clinical, pharmacologic and pharmacodynamic study of Genasense (G3139, Bcl-2 antisense oligonucleotide) and decarbazine (DTIC) in patients with malignant melanoma. San Francisco: American Society of Clinical Oncology; 2001.
23. Rai K: Genasense (Bcl-2 Antisense) Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Phase 1 and 2 Results. Philadelphia: American Society of Hematology; 2002.
24. Badros AZ: Phase I/II Rial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Patients with Relapsed Multiple Myeloma. San Diego: American Society of Hematology; 2003.
25. Iqbal J, Horsman DE, Rosenwald A, et al.: Bcl-2 Translocation Defines a Subset of DLBCL with Germinal Center B-Cell-Like Gene Expression Profiles and Preferential Expression of a Set of Genes. San Diego: American Society of Hematology; 2003.
26. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
27. Waters JS, Webb A, Cunningham D, et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000, 18:1812-1823.
28. Leonard J: Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Chicago: American Society of Clinical Oncology; 2003.